Methotrexate in the treatment of metastatic and recurrent primary transitional cell carcinoma.
Results in a series of 60 patients with recurrent or metastatic transitional cell carcinoma of the bladder confirm that methotrexate is active as a single agent. Over-all, 43 per cent of the patients with measurable metastases and 28 per cent with recurrent primary tumors responded for an average of 6 months. Response rates in both groups were influenced by the stage of the primary tumor.
D000368:Aged; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy* / Q000473:pathology; D003875:Drug Eruptions / Q000209:etiology; D006801:Humans; D007674:Kidney Diseases / Q000139:chemically induced; D008727:Methotrexate / Q000009:adverse effects / Q000627:therapeutic use*; D009362:Neoplasm Metastasis; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000473:pathology
D008727:Methotrexate